linjc16/ctgov huggingface dataset:
Analysis of Risk Factors of Postoperative Pulmonary Infection in Patients With Esophageal Cancer

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about in describe participant population. The main questions it aims to answer are: What are the risk factors of postoperative pulmonary infection in patients with esophageal cancer？ Whether we could establish a clinical prediction model to provide basis for early clinical intervention or not? Participants will describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items. If there is a comparison group: Researchers will compare insert groups to see if insert effects.

Detailed Description
-----------------
Data were collected from the electronic medical records of Xijing Hospital. Each record is entered by two team members working simultaneously to ensure data accuracy.

Official Title
-----------------
Analysis of Risk Factors of Postoperative Pulmonary Infection in Patients With Esophageal Cancer

Conditions
-----------------
Esophageal Neoplasms, Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of esophageal cancer; Radical resection of tumor for the first time; No distant metastasis was observed in preoperative examination Exclusion Criteria: Patients with preoperative pulmonary infection or symptoms of pulmonary infection; Patients with tracheal intubation assisted ventilation before surgery; Patients with preoperative lung imaging changes or abnormal white blood cells in blood routine; Patients undergoing emergency surgery; Patients with other cancers; Patients with incomplete clinical data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Infection<br>Patients who developed pulmonary infection after radical resection of tumor | |
| Without infection<br>Patients without pulmonary infection after radical resection of tumor | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pneumonia | Pulmonary infection in patients with esophageal cancer after radical resection of tumor | A week after radical resection of tumor |
The University of Freiburg Medical Center Extracorporeal Organ Support Device Registry

Study Overview
=================
Brief Summary
-----------------
A prospective registry collecting pseudonymized clinical and treatment data from all patients treated with extracorporeal organ support (i.e., VV ECMO, VA ECMO, ECPR, Impella, IABP, and others) on the wards of the Department of Interdisciplinary Medical Intensive Care at the Freiburg University Medical Center.

Official Title
-----------------
The University of Freiburg Medical Center Extracorporeal Organ Support Device Registry

Conditions
-----------------
Medical Condition Requiring Extracorporeal Organ Support

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Treatment with any kind of extracorporeal organ support Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital survival | Survival of index hospitalization (yes/no) | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Respiratory Distress Syndrome, acute respiratory failure, severe respiratory failure, cardiogenic shock, cardiac arrest, extracorporeal cardiopulmonary resuscitation
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

Study Overview
=================
Brief Summary
-----------------
This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT

Official Title
-----------------
Evaluation of Patients With Suspected Parathyroid Adenoma and Negative or Equivocal 99mTc Sestamibi SPECT/CT Using 18F Fluorocholine PET/CT

Conditions
-----------------
Parathyroid Adenoma

Intervention / Treatment
-----------------
* Drug: 18Fluorocholine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspected parathyroid adenoma (elevated serum calcium and inappropriately normal or high levels of parathyroid hormone) Negative or equivocal 99mTc Sestamibi SPECT/CT Able to provide written consent Total bilirubin ≤ 1.5 x upper limit of normal (ULN) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 xULN Karnofsky performance status of >50 (or ECOG/WHO equivalent) Women must not be pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women. Exclusion Criteria: Less than 18 years old at the time of radiotracer administration Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 60 mL/min or serum creatinine >1.5 x ULN QTcF >470 msec on electrocardiogram (ECG) or congenital long QT syndrome

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: This is a prospective, single-center, single-arm study enrolling 100 adult participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 18FCH PET/CT<br>Participant receive 18F Fluorocholine injection and approximately 45-60 minutes later receive a low dose CT scan from skull base to mid thighs, followed by a static PET emission scan over the same area. | Drug: 18Fluorocholine<br>* 18F Fluorocholine 5 mCi ± 20% administered intravenously.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of lesions detected by PET/CT for detecting parathyroid adenomas. | Inclusion criteria suggest recruiting patients with negative or equivocal SPECT/CT, so based on this there will be 0 lesions on SPECT/CT. The goal is to compare/count the number of lesions from PET/CT, if any present versus no lesions with SPECT/CT | up to 1 hour |
Community Based Treatment for (ComBaT) Glaucoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to evaluate if intervention and education can change the behavior of someone's willingness to see an eye care provider to prevent blindness and glaucoma. The researchers are investigating if adding additional resources improves participant access to care.

Detailed Description
-----------------
Outcome measures related to acceptability and feasibility are exploratory. They will not be registered or results reported.

Official Title
-----------------
Increasing Eye Care Utilization in Black Americans At High Risk For Glaucoma Using A Community-Engaged and Faith-Based Intervention

Conditions
-----------------
Glaucoma

Intervention / Treatment
-----------------
* Behavioral: ComBaT Glaucoma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Black or African American Participated in the screening examination portion of the study Exclusion Criteria: Current eye pain (> 8 out of 10) Sudden decrease in vision (within 1 week) Double vision that doesn't stop when you blink and stops no matter what eye you cover (not blurred, but seeing 2 objects) Pregnant women Prisoners Cognitive impairment- unable to give an ocular and social history Moving outside of Michigan or driving distance to the church within 6 months

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Eye concern<br>Those with a diagnosis of glaucoma or glaucoma suspect (or other concerning eye disease, such as diabetic retinopathy or macular degeneration) will be invited to participate in the ComBaT Glaucoma. | Behavioral: ComBaT Glaucoma<br>* ComBaT Glaucoma is a personalized counseling and education program about the participant's diagnosis and the importance of glaucoma follow-up care in maintaining vision.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Eye care utilization | Participants who have not seen an eye care provider for an initial clinical evaluation within 6 months of entering the program or a follow-up evaluation at 12 months will be considered underutilizers. Those who have received evaluation at 6 and 12 months will be considered normal utilizers. | Up to 14 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Eye Care, Care utilization, Community-based, Faith-based, Glaucoma
Early Results Of Coronary Artery Reconstruction For Extensive Coronary Disease

Study Overview
=================
Brief Summary
-----------------
Evaluation of early outcome obtained from coronary reconstruction with or without endarterectomy in extensive diseased coronary arteries

Official Title
-----------------
Early Results Of Coronary Artery Reconstruction For Extensive Coronary Disease

Conditions
-----------------
Coronary Reconstruction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary elective CABG patients Patch anastomosis more than 2 cm Exclusion Criteria: Patients with combined valvular procedure. Previous open heart surgery Patients with EF <40%
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Free from ischemia | Good Revascularisation | 6 Months |
A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in Upper Gastrointestinal Endoscopy

Official Title
-----------------
A Multi-center, Open-label，Single-arm Clinical Trial to Evaluate the Efficacy and Safety of Remimazolam Tosilate for Injection for Sedation in Upper Gastrointestinal Endoscopy

Conditions
-----------------
Sedation in the Upper Gastrointestinal Endoscopy

Intervention / Treatment
-----------------
* Drug: Remimazolam Tosilate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients or their guardians are able to provide a written informed consent participants undergo upper gastrointestinal endoscopy ≥18 years old, male or female 18 kg/m2≤bmi≤30kg/m2 Exclusion Criteria: Subjects to be intubated (including laryngeal mask placement); Complex endoscopic diagnosis and treatment operations are required; Severe cardiovascular disease within 6 months prior to signing the ICF; Heart rate < 50 beats/min during screening period; Subjects with poor blood pressure control during screening; Severe arrhythmias or heart disease; the circulatory system is unstable; Subjects with a history of severe cardiovascular disease, or cerebrovascular disease, or neurological disease, or mental illness Subjects with a history of drug abuse; Abnormal values of the laboratory examination; Allergic to relevant drugs ingredient or component; Pregnant or nursing women; Subjects who has participated in clinical trials of other interventions recently; Other conditions deemed unsuitable to be included.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Remimazolam Tosilate for Injection<br> | Drug: Remimazolam Tosilate<br>* bolus dose: 5mg，IV supplemental dose: 2.5mg，IV<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage(%) of paticipants who experienced successful sedation in Upper Gastrointestinal Endoscopy |  | on Day1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of subjects receiving supplemental dose for sedation |  | on Day1 | 
| The number of supplemental doses of the research drug |  | on Day1 | 
| Wake-up time. |  | on Day1 | 
| Incidence of sedation hypotension. |  | on Day1 | 
| Incidence of respiratory depression |  | on Day1 |
Study on the Protective Effect of Gastrodin on Myocardial Injury in Patients Undergoing Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
This study intends to include hypertrophic cardiomyopathy patients over 18 years old who underwent cardiac surgery in our hospital. Patients were divided into medication group and control group according to the use of gastrodin during operation. The patients ' myocardial tissue samples were collected, the postoperative prognosis data were observed and recorded, and the data were analyzed. The degree of myocardial tissue cell damage and postoperative clinical outcomes were compared between the two groups.

Official Title
-----------------
Study on the Protective Effect of Gastrodin on Myocardial Injury in Patients Undergoing Cardiac Surgery

Conditions
-----------------
Cardiac Surgical Procedures

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with hypertrophic cardiomyopathy aged≥18 years, regardless of gender; Patients undergoing elective hypertrophic cardiomyopathy outflow tract surgery; Signed informed consent, good compliance. Exclusion Criteria: suffering from more serious genetic diseases (such as immunodeficiency, thalassemia, etc.); moderate to severe malnutrition, moderate to severe anemia; persistent infection; severe preoperative underlying diseases (such as severe liver and kidney dysfunction)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GAS<br> | |
| Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Degree of myocardial cell injury | Postoperative myocardial injury marker serum concentration, postoperative cardiac function ultrasound index | During postoperative hospitalization stay, an average of about two weeks |
Intracranial Arterial Stenosis in Young Patients

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to evaluate the characteristic of intracranial arterial stenosis among young patients.

Official Title
-----------------
Intracranial Arterial Stenosis in Young Patients: a Multicenter Longitudinal Cohort Study

Conditions
-----------------
Intracranial Arterial Stenosis

Intervention / Treatment
-----------------
* Other: Routine clinical treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age < 45 years. stenosis of a major intracranial artery. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Symptomatic intracranial arterial stenosis<br> | Other: Routine clinical treatment<br>* Routine clinical treatment is based on the latest international and local guidelines<br>|
| Asymptomatic intracranial arterial stenosis<br> | Other: Routine clinical treatment<br>* Routine clinical treatment is based on the latest international and local guidelines<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ischemic stroke in territory of qualifying artery |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ischemic stroke in other territory |  | 1 year | 
| Any stroke |  | 1 year | 
| Death |  | 1 year | 
| Stenosis of the intracranial artery |  | 1 year |
Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus

Study Overview
=================
Brief Summary
-----------------
The project focuses on non-compliance in patients with systemic lupus erythematosus taking Plaquenil. More than half of patients with chronic illness are not or only poorly compliant with their treatment and lupus is one of them. The investigators want to use an already validated existing questionnaire in English, the Morisky Medication Adherence Scale 8 (MMAS 8). These results will make it possible, after a multivariate study with reference to the gold standard which is hydroxychloroquinemia, to see which exact questions in the questionnaire can be used in general medicine practices in order to detect less or non-compliant patients as early as possible.

Official Title
-----------------
Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus in a Hospital Internal Medicine Consultation

Conditions
-----------------
Lupus Erythematosus

Intervention / Treatment
-----------------
* Other: The Morisky Medication Adherence Scale


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years Patient with systemic lupus erythematosus Treatment with PLAQUENIL for > 6 months with dosage of hydroxychloroquinemia planned during the consultation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| The Morisky Medication Adherence Scale (MMAS-8)<br>The Morisky Medication Adherence Scale completed by the patients | Other: The Morisky Medication Adherence Scale<br>* The Morisky Medication Adherence Scale will be completed bu the patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Non-compliance with hydroxychloroquine treatment | to describe the non-compliance with hydroxychloroquine treatment with the Morisky Medication Adherence Scale | Day 0 |
Virtual Reality and Autobiographical Recall in Anorexia Nervosa: a Preliminary Study

Study Overview
=================
Brief Summary
-----------------
Clinical trial in patients with Anorexia Nervosa using body-swapping technique e Virtual Reality Body Size estimation tasks and Autobiographic Recall on sympton remission (EDI-3; EDE-Q), body satisfaction and perception

Official Title
-----------------
Esplorare l'Effetto di un Protocollo Combinato di Realtà Virtuale e Autobiographical Recall su Memoria, Percezione, Affetto in Pazienti Con Anoressia Nervosa: Uno Studio Preliminare

Conditions
-----------------
Anorexia Nervosa

Intervention / Treatment
-----------------
* Behavioral: Emerging Technologies and Training in Neurosciences


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Anorexia Nervosa Body mass index equal or superior to 15 kg/m2 Mother tongue Italian Semiresidential rehabilitation program Exclusion Criteria: Other eating disorders Neurological disorders , clinical history of cerebral damage, presence of psychiatric disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Anorexia nervosa<br>Female anorexia nervosa patients | Behavioral: Emerging Technologies and Training in Neurosciences<br>* Combination of body-swapping technique, Virtual Reality Body Size estimation tasks and Autobiographic Recall<br>|
| Other: Healthy controls<br>Healthy female control participants | Behavioral: Emerging Technologies and Training in Neurosciences<br>* Combination of body-swapping technique, Virtual Reality Body Size estimation tasks and Autobiographic Recall<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in estimation of body weight | Overestimation of body weight measured through Eating Disorder Inventory (EDI-3) | At baseline and after 12 months |